Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. - Test2 - elhamkhani - TriplyDB

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

http://www.wikidata.org/entity/Q27851430

about

C/EBPα Dysregulation in AML and ALL Structural and functional alterations of FLT3 in acute myeloid leukemia Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia Recurring mutations found by sequencing an acute myeloid leukemia genome Midostaurin: an emerging treatment for acute myeloid leukemia patients Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia An update of current treatments for adult acute myeloid leukemia The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy Molecular Genetic Markers in Acute Myeloid Leukemia Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Volasertib for AML: clinical use and patient consideration Post-remission therapy for acute myeloid leukemia Allogeneic stem cell transplantation in first complete remission Molecular prognostic factors in cytogenetically normal acute myeloid leukemia Emerging patterns of somatic mutations in cancer Progress in acute myeloid leukemia FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?CIViC database A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo The prognostic and functional role of microRNAs in acute myeloid leukemia Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Le RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Genomic Classification and Prognosis in Acute Myeloid Leukemia.BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects 'Acute myeloid leukemia: a comprehensive review and 2016 update'Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

P2860

a69c000b9f2f818813b909d64bf58d0f42c284ee fe9d79b914dc827d89776c092bd8d6bb1e7e05a0

P248

Q22065117-67F6D9ED-323B-46D2-BF3C-2E69B5117C41 Q24338964-AD31A2F1-11C8-4CE3-9DD7-FB400D032F70 Q24612217-C0EE4052-6FC9-4E21-872F-2FB96B102DC4 Q24634204-3211CFAD-C6B8-4484-B178-D7EA202327C0 Q26749271-DD7B0A5D-3120-4A29-821A-3499B2AFAB0F Q26768600-48AD76B8-372B-470F-8282-49D04D42F87A Q26776396-ED246ACE-61C7-467D-981A-0B97C81644D6 Q26799596-90488669-F810-4716-88BC-CFA375F9E3BF Q26799606-585F8B25-6AB1-4DB2-A80C-81C3918A1DCE Q26799609-610E3C8D-8542-418A-A191-9AE3BEC87D92 Q26801131-B333730B-625F-45F9-B6DD-279AABBEF457 Q26995867-926B2087-F82D-4439-8FA5-7AE47B93B0C7 Q26996818-99501552-B72C-4BDE-94F9-E3DC899EA7B3 Q26998811-12312999-16AF-42CC-8DF5-47579D2906E0 Q27014126-F2A6FB5C-8ADB-429C-BE0C-59A4F7A9BC1A Q27024006-89A623B2-3B1B-4C0D-B22B-838BCC7B936E Q27028163-E447D083-2493-49D1-BC46-4444339101EE Q27612411-01D6D339-6A7D-4CBE-A1CE-64065390CCE5 Q27684428-41C42942-4A16-4E75-9A9E-0F503BA83C76 Q27693865-7AA70C29-E250-4DAD-AA4E-06FCA3C9A6DD Q27851460-C7856262-C0C5-4B48-A1A7-D67F53F7DB10 Q27851545-95517FB8-F10A-4E7C-A03E-6907C5DBD181 Q27851565-227B033E-865E-42A3-B567-CAD67DA1491F Q27851621-CD58B809-F8AA-4D92-9666-56DEE08A1808 Q27851642-3F7AB4BD-B947-427A-8420-A7A0E50E1A6B Q27851679-984C2440-50E6-468E-9A06-BD29BBCF4470 Q27851686-263DF659-4A61-4183-814C-05D11C7BFABD Q27851694-C14D23CC-74C6-4F7C-8B58-C52E26B34642 Q27851713-AE9C143F-88DD-41BC-B754-A6857AC9F72B Q27851726-65A68F7D-4DB1-41C7-B658-0FE45280AB3A Q27851839-BF8BED26-EE0B-4813-92F1-E692FDDBCBA6 Q27853004-AC82548F-9C64-499A-9DCB-D01BA681DFEF Q27853009-361F2423-0EB5-4583-95CB-0EA3B9A60413 Q27853031-03989D68-8663-47B6-9B29-76F1FB1A805C Q27853381-F1FF9D77-336B-4F29-B73E-31EA126D13D9 Q27853389-2D4BF86C-9630-4D0E-A476-025A1EB46AD5 Q28066765-8570046E-C751-4AD0-BD22-B201383EC39B Q28072539-DE8EAB9A-C999-4258-8ACB-15C9FB6DA8A1 Q28073464-E93CD32D-3CF2-4E7D-BBFB-F2D69A7DE784 Q28289859-11963B99-2721-45F3-9B90-A8ED72F4F9F6

P2860

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

http://www.wikidata.org/entity/Q27851430

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@ast

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@en

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@nl

type

label

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@ast

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@en

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@nl

prefLabel

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@ast

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@en

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@nl

P1433

Q27851430-3542712A-1BE5-48E1-9C56-1C6E36DCEFAD

P1476

Q27851430-2CC5C00D-264A-47CB-88EA-72E1AEBAAB36

P2093

Q27851430-04654F70-EA62-4154-B15E-902C1D3356B0

Q27851430-08949EAA-FC62-4549-988B-6FED70F69B33

Q27851430-17634AC1-E021-4538-88D7-E021819D816E

Q27851430-285F2F3B-F07A-47AE-AD1D-31891FC6D071

Q27851430-286CE225-9833-4E8D-9B9F-E593901C9461

Q27851430-3BB8EAA7-1432-496E-BF33-DCD9C5009F1D

Q27851430-687D3BEC-2669-49FD-B069-CC3B5BAF0BDA

Q27851430-9AA3F94F-F006-4532-82C0-FB8965F62705

Q27851430-B35B0BDB-3928-46B4-A992-7EBAE6776A32

Q27851430-BE1DBF05-0903-45AE-ADC6-C3F7CDFC9957

P304

Q27851430-DA524D6F-3606-408A-82E5-ED398F1F77D3

P31

Q27851430-4C045323-57C0-41C3-8EF2-C35C1F37D5AA

P3181

Q27851430-F8B521CE-5A53-4FCF-8D48-4ED31391CA01

P356

Q27851430-FEA6E484-CA1C-4A22-8005-BD235FEFD90A

P407

Q27851430-69A0924C-E6E8-4DAD-8A0B-D0BEC7E23140

P433

Q27851430-2F227D72-E979-4AB7-9CF4-A25A880D7089

P478

Q27851430-926B5344-DA8A-4BB8-87F5-3AEB6B3D0988

P50

Q27851430-677AADCB-8A2D-454B-BBA1-C05521837C2F

Q27851430-C6DF195B-3663-4DF6-8EFC-06CDDD0D7E79

Q27851430-D8FABBC9-8443-460B-851C-4A37B1D97ADA

P577

Q27851430-DA184AE6-340E-4A19-B217-668B22296DA9

P698

Q27851430-455702A8-1489-466A-B1A7-EDB84F2E3B37

P921

Q27851430-56F031AA-824B-411D-8B98-8AA1FCEF3535

P3181

P356

P1433

The New England Journal of Medicine

P1476

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

@en

P2093

Andrea Corbacioglu

http://www.w3.org/2001/XMLSchema#string

Arnold Ganser

http://www.w3.org/2001/XMLSchema#string

Axel Benner

http://www.w3.org/2001/XMLSchema#string

Daniela Späth

http://www.w3.org/2001/XMLSchema#string

Gerhard Heil

http://www.w3.org/2001/XMLSchema#string

Jürgen Krauter

http://www.w3.org/2001/XMLSchema#string

Lars Bullinger

http://www.w3.org/2001/XMLSchema#string

Marianne Habdank

http://www.w3.org/2001/XMLSchema#string

Michael Morgan

http://www.w3.org/2001/XMLSchema#string

Richard F Schlenk

http://www.w3.org/2001/XMLSchema#string

P304

1909-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1781213

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA074306

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

358

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Döhner

Konstanze Döhner

Brigitte Schlegelberger

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18450602

http://www.w3.org/2001/XMLSchema#string

P921